IL270329A - - Google Patents

Info

Publication number
IL270329A
IL270329A IL27032919A IL27032919A IL270329A IL 270329 A IL270329 A IL 270329A IL 27032919 A IL27032919 A IL 27032919A IL 27032919 A IL27032919 A IL 27032919A IL 270329 A IL270329 A IL 270329A
Authority
IL
Israel
Application number
IL27032919A
Other languages
English (en)
Other versions
IL270329B2 (en
IL270329B1 (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of IL270329A publication Critical patent/IL270329A/en
Publication of IL270329B1 publication Critical patent/IL270329B1/en
Publication of IL270329B2 publication Critical patent/IL270329B2/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/55IL-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL270329A 2017-05-02 2018-05-02 Immunotherapeutic tumor treatment method IL270329B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762500486P 2017-05-02 2017-05-02
US201762502051P 2017-05-05 2017-05-05
PCT/US2018/030714 WO2018204528A1 (en) 2017-05-02 2018-05-02 Immunotherapeutic tumor treatment method

Publications (3)

Publication Number Publication Date
IL270329A true IL270329A (https=) 2019-12-31
IL270329B1 IL270329B1 (en) 2025-08-01
IL270329B2 IL270329B2 (en) 2025-12-01

Family

ID=64016803

Family Applications (1)

Application Number Title Priority Date Filing Date
IL270329A IL270329B2 (en) 2017-05-02 2018-05-02 Immunotherapeutic tumor treatment method

Country Status (11)

Country Link
US (1) US12054553B2 (https=)
EP (1) EP3628010A4 (https=)
JP (1) JP7165680B2 (https=)
KR (1) KR102785429B1 (https=)
CN (1) CN110582300B (https=)
AU (1) AU2018261102B2 (https=)
CA (1) CA3062291A1 (https=)
IL (1) IL270329B2 (https=)
MA (1) MA48862A (https=)
MX (1) MX2019013071A (https=)
WO (1) WO2018204528A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110582300B (zh) 2017-05-02 2024-08-02 尼克塔治疗公司 肿瘤免疫治疗性治疗方法
AU2019271148B9 (en) 2018-05-14 2025-05-29 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
CA3100005A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
TW202500188A (zh) * 2019-01-04 2025-01-01 丹麥商阿仙帝斯製藥公司 模式辨別受體(pattern recognition receptor)促效劑的共軛物
EP3954382A4 (en) * 2019-04-05 2022-12-21 Sumitomo Pharma Co., Ltd. WATER SOLUBLE ADJUVANT AND COMPOSITION CONTAINING IT
KR20220023988A (ko) 2019-05-14 2022-03-03 웨어울프 세라퓨틱스, 인크. 분리 모이어티 및 이의 사용 방법
JP2022553370A (ja) * 2019-10-25 2022-12-22 ネオルーキン セラピューティクス,インコーポレイティド Il-2受容体作動薬の投与方法
BR112022009110A2 (pt) 2019-11-14 2022-07-26 Werewolf Therapeutics Inc Polipeptídeos de citocina ativáveis e métodos de uso destes

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4992540A (en) 1984-11-28 1991-02-12 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US4810646A (en) 1984-11-28 1989-03-07 Massachusetts Institute Of Technology Glucan compositions and process for preparation thereof
US5028703A (en) 1988-03-11 1991-07-02 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US5032401A (en) 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
DE10248141B4 (de) * 2002-10-11 2007-04-19 Universitätsklinikum Hamburg-Eppendorf Nukleinsäuren und deren Verwendung für die Gentherapie
AU2003300184B8 (en) 2002-12-30 2009-12-03 3M Innovative Properties Company Immunostimulatory combinations
WO2004084949A2 (en) 2003-03-20 2004-10-07 Xencor Generating protein pro-drugs using reversible ppg linkages
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
BRPI0611872B8 (pt) 2005-06-16 2021-05-25 Nektar Therapeutics reagente polimérico, conjugado, método para preparação de um conjugado e composição farmacêutica
WO2007109564A2 (en) 2006-03-17 2007-09-27 University Of Massachusetts Yeast cell particles as oral delivery vehicles for antigens
US20080241139A1 (en) * 2006-10-31 2008-10-02 Regents Of The University Of Colorado Adjuvant combinations comprising a microbial tlr agonist, a cd40 or 4-1bb agonist, and optionally an antigen and the use thereof for inducing a synergistic enhancement in cellular immunity
KR101671537B1 (ko) 2008-08-11 2016-11-01 넥타르 테라퓨틱스 다분지형 중합체 알카노에이트 컨쥬게이트
MX2012012833A (es) * 2010-05-07 2012-11-30 Baylor Res Inst Cebado cruzado de celulas t cd8 positivas humanos moderada por inmunoreceptores de celulas dendriticas (dcir).
ES2866674T3 (es) 2010-11-12 2021-10-19 Nektar Therapeutics Conjugados de una fracción de IL-2 y un polímero
WO2012088422A1 (en) * 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
US20140199347A1 (en) 2011-02-10 2014-07-17 University Of Louisville Research Foundation, Inc. Adjuvant compositions with 4-1bbl
MX385194B (es) * 2014-02-21 2025-03-14 Nektar Therapeutics India Pvt Ltd Agonistas il-2rbeta-selectivos en combinación con un anticuerpo anti-ctla-4 o un anticuerpo anti-pd-1.
US10149887B2 (en) 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
KR102619747B1 (ko) * 2017-01-10 2023-12-29 넥타르 테라퓨틱스 Tlr 효현제 화합물의 다중-아암 중합체 컨쥬게이트 및 관련 면역 요법적 치료 방법
CN110582300B (zh) 2017-05-02 2024-08-02 尼克塔治疗公司 肿瘤免疫治疗性治疗方法
EP3668548A2 (en) * 2017-08-17 2020-06-24 Nektar Therapeutics Immunotherapeutic tumor treatment method

Also Published As

Publication number Publication date
CN110582300A (zh) 2019-12-17
IL270329B2 (en) 2025-12-01
MA48862A (fr) 2020-04-01
KR102785429B1 (ko) 2025-03-21
EP3628010A4 (en) 2021-02-17
WO2018204528A1 (en) 2018-11-08
JP2020518610A (ja) 2020-06-25
CN110582300B (zh) 2024-08-02
MX2019013071A (es) 2019-12-11
JP7165680B2 (ja) 2022-11-04
CA3062291A1 (en) 2018-11-08
AU2018261102A1 (en) 2019-11-07
US12054553B2 (en) 2024-08-06
IL270329B1 (en) 2025-08-01
AU2018261102B2 (en) 2025-01-23
US20210292425A1 (en) 2021-09-23
KR20190141760A (ko) 2019-12-24
EP3628010A1 (en) 2020-04-01

Similar Documents

Publication Publication Date Title
BR122021024397A2 (https=)
BR122021000189A2 (https=)
BR112019008823A2 (https=)
BR112020006084A8 (https=)
BR122022025811B8 (https=)
BR202018014992U2 (https=)
BR122021023687A2 (https=)
BR122021014832A2 (https=)
BR122022003518A2 (https=)
BR112020008820A2 (https=)
BR202017025154U2 (https=)
BR102017023327A2 (https=)
BR202017021228U2 (https=)
BR202017020981U2 (https=)
BR202017017068U2 (https=)
BR202017016984U2 (https=)
BR202017016924U2 (https=)
BR102017015495A2 (https=)
BR102017015250A2 (https=)
BR102017014430A2 (https=)
BR202017012548U2 (https=)
BR202017011220U2 (https=)
BR202017010814U2 (https=)
BR202017010373U2 (https=)
BR202017009870U2 (https=)